Geron to Present at Upcoming Investor Conferences

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) has announced that CEO John A. Scarlett will present at three major investor conferences in New York City. The events include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, and the Baird 2022 Global Healthcare Conference on September 14, 2022. Webcasts will be available on Geron's website and archived for 30 days. Geron focuses on developing its first-in-class telomerase inhibitor, imetelstat, for treating hematologic malignancies.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present in-person at the following investor conferences in New York City:

• Morgan Stanley 20^th Annual Global Healthcare Conference
  Fireside chat on Monday, September 12, 2022, at 5:25 p.m. ET

• H.C. Wainwright 24^th Annual Global Investment Conference
  Corporate presentation on Tuesday, September 13, 2022, at 12:30 p.m. ET

• Baird 2022 Global Healthcare Conference
  Fireside chat on Wednesday, September 14, 2022, at 1:25 p.m. ET

A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of Geron’s website under Events. Following each scheduled conference event, the related webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in relapsed/refractory myelofibrosis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005110/en/

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

What are the dates for Geron's presentations at investor conferences in September 2022?

Geron's presentations will occur on September 12, 13, and 14, 2022.

Where can I watch the webcasts of Geron Corporation's presentations?

Webcasts can be viewed on Geron's Investor Relations website, where they will also be archived for 30 days.

What is the focus of Geron Corporation's clinical trials?

Geron is conducting trials for its telomerase inhibitor, imetelstat, aimed at hematologic malignancies.

What is the significance of the events John A. Scarlett is presenting at for GERN?

These investor conferences are significant for GERN as they provide opportunities to engage with investors and raise awareness of their clinical developments.

What is the ticker symbol for Geron Corporation?

The ticker symbol for Geron Corporation is GERN.